Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report

Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report

Abstract Background The treatment of advanced or metastatic renal cell carcinoma (RCC) has drastically changed since the approval of immune checkpoint therapy. Nivolumab is a treatment option for patients with metastatic RCC, previously treated with targeted antiangiogenic therapy. The efficacy of n...

Full description

Bibliographic Details
Main Authors: Go Noguchi, Sohgo Tsutsumi, Masato Yasui, Shinji Ohtake, Susumu Umemoto, Noboru Nakaigawa, Masahiro Yao, Takeshi Kishida
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Urology
Subjects:
Non-clear renal cell carcinoma
Sarcomatoid differentiation
Immune-checkpoint inhibitor
Nivolumab
Online Access:http://link.springer.com/article/10.1186/s12894-018-0339-2

Internet

http://link.springer.com/article/10.1186/s12894-018-0339-2

Similar Items